David R. Boyko
David R. Boyko is Director, Global Business Development for Merck Animal Health (known as MSD Animal Health outside the United States and Canada), a part of Merck & Co., Inc., Kenilworth, NJ. In this role, David is responsible to identify, evaluate, negotiate and execute licensing and business development transactions for animal health products and services, including newly emerging animal diseases, biopharmaceuticals, vaccines, drug and vaccine delivery and new, digital technologies. Geographically, he focuses on opportunities for the North American business units.
Underpinning that role are more than twenty years of legal practice, with twenty of those years as a deal lawyer, business partner and counselor in the life sciences industry. His legal career includes extensive experience in corporate development and licensing activities for prescription, over-the-counter health and animal health products and technologies, as well as in the new area of digital health. He has advised executive and senior management levels on a broad range of legal issues, including M&A, regulatory, commercial, corporate governance and litigation, managed lawyers and controlled outside counsel annual budgets in excess of $2MM. David also has been Division Counsel for Healthcare Services & Solutions, Merck's business unit for innovative, non-drug healthcare solutions, a Senior Counsel in the Corporate Transactions Groups of both Merck and Schering-Plough, and an executive officer for Xenogen Corporation. In private practice, David was with the law firms of Wilson Sonsini Goodrich & Rosati and Fried, Frank, Harris, Shriver & Jacobson. He has a number of published articles on intellectual property and antitrust matters, and has chaired licensing panels at several annual meetings of the Association of Corporate Counsel.
David earned his J.D. degree from the University of California Los Angeles, his M.A. degree in International Relations from the University of Southern California and his B.S. degree in Mechanical Engineering from Cornell University. David is also a veteran, having served eight years of active duty as a U.S. Air Force officer.
Todd B. Richter C.F.A
Todd Richter is currently a Senior Managing Director at Guggenheim Partners. His primary focus is on the healthcare services field including managed care/payer services, physician-related businesses and all forms of distribution and outsourcing. In addition, Mr. Richter is responsible for Guggenheim Partners’ coverage of the global animal health field. From 2016 until 2018 Mr. Richter was Vice Chairman of Global Banking at Barclays. From 1999 to 2016 Todd Richter was a Senior Managing Director in the Global Healthcare Corporate & Investment Banking Group at Bank of America Merrill Lynch. From 1981 to 1999, Mr. Richter served as the head of the healthcare services analytical team for Morgan Stanley. Todd Richter earned a B.B.A. in Finance from the College of William & Mary in 1979 and an M.B.A. in Finance with Honors from Indiana University in 1981. Todd was recognized 16 times as a member of the Institutional Investor’s All-America Research Team. He was also listed many times among the Wall Street Journal’s “All-Star” analysts and on the Reuters research poll. Mr. Richter is currently a member of the Board of Directors (Vice Chairman) of Bideawee, one of the nation’s leading animal rescue organizations; a member of the Board of Directors at the Stratton Mountain School (SMS) in Stratton, Vermont, a member of the Board of Directors at Animal Lighthouse Rescue (ALR), and a member of the Dean’s Council for the Kelley School of Business at Indiana University. Finally Mr. Richter is on the Board and faculty of the Columbia University Mailman School of Public Health teaching a course on healthcare consolidation to MPH and MHA candidates.
Scott DeWire
Scott is responsible for immuno-oncology partnerships and licensing at Boehringer Ingelheim Pharmaceuticals Inc. Scott learned to pipette as an intern and later bench scientist with Pfizer Animal Health in his hometown of Groton, CT. After Pfizer, he earned a PhD from the University of North Carolina, and completed his postdoc at Duke University with Robert Lefkowitz (2012 Nobel Prize). Out of his postdoc, Scott co-founded Trevena Inc, a biotech company focused on GPCR biology. Since joining Boehringer in 2012, Scott has held various roles in the research group before joining BD&L in 2016.
Scott has a lifelong love of animals, and he and his family currently have a menagerie of animals that includes his three cherished beagles.
Milton Boyle
Milton has over 30 years experience in animal agriculture and animal health. He started his career as a commercial poultry geneticist and was head of R&D for 2 primary poultry breeders (Avian Farms International and Hubbard Farms). Since 2007, he has worked for Merial and now Boehringer Ingelheim as the business development partner for R&D focusing on licenses and research collaborations.
